Acrivastine

  • CAT Number: I013652
  • CAS Number: 87848-99-5
  • Molecular Formula: C₂₂H₂₄N₂O₂
  • Molecular Weight: 348.44
  • Purity: ≥95%
Inquiry Now

Acrivastine (Cat No.:I013652) is a short-acting histamine 1 receptor antagonist used in the study of allergic rhinitis. It is suitable for the treatment of allergic rhinitis, hay fever, urticaria, eczema, skin pruritus, etc.

Catalog Number I013652
CAS Number 87848-99-5
Molecular Formula

C₂₂H₂₄N₂O₂

Purity 95%
Target Histamine Receptor
Solubility DMSO: 10.45 mg/mL (Need ultrasonic)
Storage 2-8°C
IUPAC Name (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid
InChI InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
InChIKey PWACSDKDOHSSQD-IUTFFREVSA-N
SMILES CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC(=N3)C=CC(=O)O
Reference

[1]. Brogden RN, et al. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991 Jun;41(6):927-40.<br>[2]. Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. Br J Clin Pract. 1989 Jan;43(1):11-4.

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!